(E)-N'-(4-chlorobenzylidene)-5-methyl-1H-pyrazole-3-carbohydrazide as a potential PI3Kα targeting scaffold, synthesis, X-ray crystallography, DFT, molecular docking, molecular dynamics simulations, and MMGBSA analysis

El Hassani I. A., Isa M. A., El Hassani A. A., Demir C. B., Dege N., Alzahrani A. Y. A., ...Daha Fazla

JOURNAL OF MOLECULAR STRUCTURE, cilt.1359, 2026 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 1359
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1016/j.molstruc.2026.145569
  • Dergi Adı: JOURNAL OF MOLECULAR STRUCTURE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, Chimica, Compendex, INSPEC
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Cancer remains a major global health challenge. Targeting the PI3K/Akt/mTOR pathway, particularly PI3K alpha, is a promising anticancer strategy. In this study, a novel pyrazole derivative, E-CMPC, was designed, synthesized, and structurally characterized, including 1H NMR, 13C NMR, ESI-MS, and single-crystal X-ray diffraction. Quantum chemical calculations, Molecular docking, molecular dynamics simulations, and MMGBSA analysis indicated favourable binding behaviour and dynamic stability within a PI3K-like catalytic environment, modelled using the VPS34 kinase domain as a structural surrogate. In silico ADMET analysis indicated favorable pharmacokinetic properties and low toxicity. However, the in silico studies were conducted using a class III phosphoinositide 3-kinase (VPS34) catalytic domain as a structural surrogate to explore conserved PI3K family binding features. Therefore, these computational results highlight E-CMPC as a promising in silico lead candidate, warranting further experimental validation as a PI3K alpha-targeted anticancer agent.